Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy

Immunotherapy

Volumn 7, Issue 8, 2015, Pages 847-849

  Gough, Michael J ^a   Crittenden, Marka R ^a,b   Young, Kristina H ^a,b  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b Oregon Clinic   (United States)

Author keywords

cancer; dose; fractionation; immunotherapy; radiation; SBRT; tumor

Indexed keywords

CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOTHERAPY; REVIEW; STANDARD; STEREOTACTIC BODY RADIATION THERAPY; ANIMAL; COMPARATIVE STUDY; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; RADIATION RESPONSE; TREATMENT OUTCOME; TRENDS;

ANIMALS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 84942104262     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/IMT.15.58     Document Type: Review

References (14)

1. Young KH, Newell P, Cottam B et al. TGF inhibition prior to hypofractionated radiation enhances efficacy in preclinical models. Cancer Immunol. Res. (2014).
2. Seung SK, Curti BD, Crittenden M et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci. Transl. Med. 4(137), 137ra174 (2012).
3. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved? Int. J. Radiat. Oncol. Biol. Phys. 88(2), 254-262 (2014).
4. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622), 1155-1159 (2003).
5. Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma: the importance of dose and fractionation. Front. Oncol. 4, 1 (2014).
6. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances mhc class i expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203(5), 1259-1271 (2006).
7. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64(12), 4328-4337 (2004).
8. Klug F, Prakash H, Huber PE et al. Low-dose irradiation programs macrophage differentiation to an inos(+)/m1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24(5), 589-602 (2013).
9. Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. doi:10.1016/j. canlet.2015.03.024 (2015) (Epub ahead of print).
10. Dewan MZ, Galloway AE, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immunemediated abscopal effect when combined with anti-CTLA-4 antibody. Clinical Cancer Res. 15(17), 5379-5388 (2009).
11. Demaria S, Kawashima N, Yang AM et al. Immunemediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2), 728-734 (2005).
12. Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin. Cancer Res. 15(2), 597-606 (2009).
13. Milas L, Mason KA, Ariga H et al. CPG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 64(15), 5074-5077 (2004).
14. Mason KA, Ariga H, Neal R et al. Targeting toll-like receptor 9 with CPG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin. Cancer Res. 11(1), 361-369 (2005).